Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.


Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Related Post

Redenlab selected for world-first international collaboration investigating neurofilament light chain and voice for diagnosing Dementia

  • Posted on 30 March, 2023
    Redenlab are partnering with Monash university, University of Melbourne, Eastern Health, and Invicta to deliver this world-first collaboration investigating neurofilament...
    Read more

    Simons Searchlight: Researcher Profile: Angela Morgan, PhD

    • Posted on 30 March, 2023
      Angela Morgan, PhD, is a National Health and Medical Research Council Elizabeth Blackburn Fellow and leads the Speech and Language...
      Read more

      The L16HTHOUSE Study

      • Posted on 30 March, 2023
        L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
        Read more